REGISTERED
on 19 Nov 2024
Last Applicant/ Owned by
Foresterhill Aberdeen AB25 2ZP
GB
Serial Number
79379490 filed on 19th Apr 2023
Registration Number
7567642 registered on 19th Nov 2024
Correspondent Address
Charlene M. Krogh
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
ELASMOGEN
Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory Read More
Classification Information
Class [044]
Medical, Beauty & Agricultural Services
Medical services; medical advisory services relating to the treatment, relief and prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; preparation and provision of medical reports to patients and medical professionals; preparation and provision of medical information in the form of reports on pharmaceuticals, advanced therapy medicinal products, and therapeutic antibodies to patients and medical professionals; consultancy, advice and information in the field of healthcare, pharmaceuticals and advanced therapy medicinal products
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [042]
Computer & Software Services & Scientific Services
Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceutical products; research services in the field of diagnostic preparations; scientific laboratory services; custom design and development of biochemical assays; scientific and medical research laboratory services; research and development of new products for others; scientific research and analysis in the field of drug discovery; new product development in the field of pharmaceuticals for others; scientific advisory services, namely, medical advisory services related to pharmaceutical development and testing; scientific research consultancy in the field of cancer research, inflammatory disease research, auto-inflammatory disease research, autoimmune disease research, eye disease and disorder research, and intracellular delivery research of pharmaceuticals and therapeutics; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; consulting services for others in the field of design, planning, and implementation and project management of scientific research and clinical trials; providing scientific research information; technical advisory services relating to scientific and clinical research; provision of technical and scientific information and consultancy in relation to the aforesaid services.
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations agents, and substances for medical purposes; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medical diagnosis purposes; DNA and antibodies and proteins that stimulate cells for medical use; DNA, antibodies and proteins for therapeutic use for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations for medical purposes; reagents for medical use
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79379490
Mark Type
No Service Mark
Attorney Docket Number
No T321120.IB-U
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 19th Nov 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 19th Nov 2024 | REGISTERED-PRINCIPAL REGISTER |
| 03rd Sep 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 03rd Sep 2024 | PUBLISHED FOR OPPOSITION |
| 14th Aug 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 31st Jul 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 29th Jul 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 29th Jul 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 29th Jul 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 19th Feb 2024 | REFUSAL PROCESSED BY IB |